Drug Testing and Analysis · 2016 · 37 citations · 13 references
PharmacyMedicinal ChemistryPharmacologyBiochemical PharmacologyChromatographic AnalysisMass Spectrometric AnalysisBioanalytical Method ValidationCannabinoid PharmacologyClinical AnalysisToxicological Drug ScreeningToxicological Screening Of PharmaceuticalsBlood Cannabinoid AnalysisInternal StandardsLiquid Chromatography-mass SpectrometryLiquid Chromatography-mass Spectrometry AnalysisMass Spectrometric Drug AnalysisMass Spectrometric ScreeningPharmacological ScreeningTandem Mass Spectrometry
We describe the development and validation of a method for the screening and confirmation of a range of chemically diverse synthetic cannabinoid drugs in human whole blood. The method targets the better known arylindole compounds as well as the emerging aminocarbonyl/ carboxamide (NACA) compounds. The approach consists of two separate extraction procedures designed to optimize recovery of each of these two classes, followed by analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The most significant novel compounds added were AB-FUBINACA, ADBICA, 5 F-ADBICA, ADB-PINACA, ADB-FUBINACA, ADB-FUBINACA, 5 F-ADB-PINACA, 5 F-ADB-PINACA, AB-PINACA, AB-CHMINACA, and ADB-CHMINACA. A third procedure is described for the quantitative confirmation of those compounds for which deuterated internal standards permitted quantitative analysis, including JWH-018, JWH-122, JWH-081, JWH-210, AM-2201, XLR-11, and UR-144. The methods were successfully validated according to Scientific Working Group in Forensic Toxicology (SWGTOX) protocol for 34 compounds in common use in the United States in the period of 2014 and 2015, although other substances, unknown at the time may have been introduced to the market over the same time period. The method was determined to be free from carry-over between samples, and no interference was found from other common therapeutic abused or novel psychoactive drugs. The methods were applied to the analysis of 1142 blood samples from forensic investigations, including post-mortem examinations and driving impairment cases. The drugs most frequently detected were AB-CHMINACA (18.6%), ADB-CHMINACA (15%), XLR-11 (5.5%), AB-FUBINACA (4.5%), AB-PINACA (3.9%), and ADB-FUBINACA (2.3%). Copyright © 2016 John Wiley & Sons, Ltd.
13
Pharmacology, Toxicology, and Adverse Effects of Synthetic Cannabinoid Drugs.
Susan M. R. Gurney, Karen S. Scott, Sherri L. Kacinko et al. · PubMed · 2014 · 254 citations
Medicine, Pharmacology, Toxicology +17
Sherri L. Kacinko, Allan Xu, Joseph W. Homan et al. · Journal of Analytical Toxicology · 2011 · 114 citations · Full text
Synthetic Cannabinoids in Oral Fluid
Cynthia Coulter, Maud Garnier, Christine Moore · Journal of Analytical Toxicology · 2011 · 105 citations
Pharmacy, Pharmacology, Toxicology +17